Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose Escalation, Safety and Tolerability Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

NCT01905813 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT01905813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01905813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose Escalation, Safety and Tolerability Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2013
Completion date
February 26, 2026
Enrollment
121 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell malignancies